Suven Life Sciences gets patent approval from New Zealand

Suven Life Sciences has received patent rights from New Zealand for two products The patents are valid through 2029 and 2030, respectively. The drugs granted patents are used in the treatment of cognitive impairment associated with neurodegenerative disorders, such as Alzheimer, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia. The stock on Friday closed with a marginal gain at ₹72.